Influenza nasal spray and injection (FOI)

Request 

Please provide the following information related to the 2022 flu nasal spray and injection:

A

Name(s) of manufacturer(s).

B

Product name(s).

C

Batch number(s) Nasal Flu.

D

Copy of full medical insert(s) detailing full list of ingredients and regulatory information including approval.

E

Name and position of individual responsible for approving the 2022 programme.

F

Evidence of the Government of Jersey providing the opportunity for informed consent such as clear directions on how a member of the public could source the required product and regulatory information without completing a Freedom of Information request.

Response 

A

AstraZeneca UK Limited. 

B

The nasal spray product name is Fluenz Tetra. 

The injection product name is Qive Quadrivalent Influenza vaccine Sanofi Pasteur Batch no LOT434703111. Qivc cell based Quadrvalent Influenza Vaccine Seqirus (batch no LOTP100455524. 

C

PH2004, PF3032, PH2003, PF3033, PH2003.

D

The nasal spray information is as follows:

Package leaflet: Information for the user Fluenz® Tetra nasal spray suspension (medicines.org.uk)

The injection information is as follows: 

Package leaflet: Information for the user Quadrivalent Influenza Vaccine (medicines.org.uk)

Package leaflet: Information for the user Adjuvanted Quadrivalent Influenza Vaccine (medicines.org.uk)

Package leaflet: Information for the user Cell-based Quadrivalent Influenza Vaccine (medicines.org.uk)

E

Richard Renouf, who at the time was Minister of Health and Social Services.

F

For an individual to be able to make 'informed' consent, evidence-based information is readily available in multiple formats to islanders. This is not limited to the website-based information, it also includes Manufacturer Vaccine Information Leaflets, social media messages and verbal discussions between the individual attending for vaccination and vaccinator regarding risks and benefits.

For consent in relation to children, the school children's programme is as follows:

• Email via education to parents of children eligible with contact details for any questions and informing them to expect an envelope from school containing:
• Parental letter with reasons why to vaccinate your child. 
• Information leaflet with website address for further information, contact telephone number for queries, list of ingredients etc:
  
• FLUENZ Tetra, INN-influenza vaccine (live attenuated, nasal) (medicines.org.uk) ,
• Consent form advising parents to read the leaflet before completing the form
  

The preschool programme is as follows:

• Parental letter sent to child's home address with reasons why to vaccinate your child plus the Information leaflet with website address for further information, contact telephone number for queries, list of the of ingredients etc:
• FLUENZ Tetra, INN-influenza vaccine (live attenuated, nasal) (medicines.org.uk)
• Consent form held at nursery if vaccine is to be delivered there.